News | February 05, 2015

IBA Dosimetry’s CAREprogram Supports the UICC and World Cancer Day 2015

Activities are planned to raise awareness of the importance of World Cancer Day

IBA (Ion Beam Applications S.A.), a global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, is proud to support the Union for International Cancer Control (UICC) by participating in World Cancer Day on February 4, 2015.  IBA’s mission to “Protect, Enhance and Save Lives” reflects the understanding that lives are impacted by the efforts of all of IBA’s employees in developing the solutions, education and services for fighting cancer. World Cancer Day offers the perfect platform to take a moment and focus on this cause from a very personal aspect.

“Cancers figure among the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012”. The number of new cancer cases is expected to increase to 24 million by 2035” according to the UICC.  “Unless urgent action is taken to raise awareness about cancer and develop practical strategies to address the disease, millions of people will continue to die. Sadly, the greatest increase in cancer is projected to hit low- and middle-income countries, those least equipped to cope with the social and economic impact of the disease.”

IBA Dosimetry’s activities to support World Cancer Day include an internal awareness campaign, participation in World Cancer Day 2015 Thunderclap (a global social media blast), hosting a Healthy Choices Lunch, and encouraging employees to sign up for a “Do Something!” challenge. The “Do Something!” challenge gives people the opportunity to make intentional choices that support the goals of the Word Cancer Declaration agenda. By committing to make healthier food choices, quit smoking, start a fitness program or support any of the many cancer foundations there is something that everyone can do.  The theme for this year’s World Cancer Day is “Not Beyond Us.” 

“When cancer hits a family, life changes on the spot and often drastically,” said Rob Plompen, president of IBA Dosimetry. “During my past 17 years at IBA Dosimetry, I have had the opportunity to visit many cancer centers around the world. Whether in highly equipped Radiation Therapy centers or in less developed countries, the passion of the professionals I met working in every center is a common one: to fight this evil disease and, above all, to provide a better quality of life for their patients. At IBA Dosimetry, more than 220 employees support these professionals every day in their battle against cancer.  By providing Quality Assurance equipment, education and services to ensure safe treatment of patients, we are proud of this mission and fortunate that we can contribute in the joint battle to defeat cancer. It’s Not Beyond Us.”

“We are witnessing an unavoidable increase in the number of cancer cases throughout the world.To defeat this terrible disease, healthcare specialists need the best solutions to diagnose and treat cancer. Proton therapy is one of those solutions. It is considered as the most advanced treatment to fight against cancer. Day after day, together with our partners in oncology, we strive to make proton therapy accessible to as many patients as possible worldwide as it reduces side effects and improve considerably the quality of life. These two advantages are particularly important to ensure a bright future for children. At IBA, we are developing innovative solutions to push  back the limits of technology and complete our mission to Protect, Enhance and Save Lives. Cancer is not beyond us!” added Olivier Legrain, chief executive officer of IBA.

IBA is committed to continuing its education and advocacy to ensure that all cancer patients and their families are aware of the technologies and treatments available to them. 

For more information: www.iba-dosimetry.com

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...